Download Bibliografía - Centro de Salud La Alamedilla

BIBLIOGRAFÍA
Bibliografía
1.
Grupo de prevención cardiovascular del programa de actividades preventivas y promoción
de la salud (PAPPS) de la Sociedad Española de Medicina de Familia y Comunitaria
(semFYC). Guía de prevención cardiovascular. Madrid: Sersa; 1996.
2.
Villar F, Maiques A, Brotons C, Torcal J, Lorenzo A, Vilaseca J, Banegas JR, Rodríguez F
y Guillen V. Recomendaciones preventivas cardiovasculares: aplicaciones prácticas del
riesgo cardiovascular. Atención Primaria 1999; 24 (sup):66-75.
3.
Muñiz J y Brotons C. Epidemiología de la enfermedad cardiovascular. En Brotons C.
editor. Factores de riesgo de la enfermedad cardiovascular. Monografías de atención
primaria. Barcelona: Doyma; 1991. p. 1-12.
4.
International Task Force for Prevention of Coronary Heart Disease. Coronary Heart
Disease: Reducing the risk. Nutr Metab Cardiovasc Dis 1998; 8:205-271.
5.
Tunstall-Pedoe H, Kulasmaa K, Mähönen M, Tolonen H, Ruokoski E, Amouyel P.
Contribution of trends in survival and coronary-event rates to changes in coronary heart
disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet
1999; 353:1547-57.
6.
Medrano MJ, Almazán J, Sierra MJ, Olalla MT. Situación epidemiológica de las
enfermedades cardiovasculares arterioscleróticas: mortalidad y morbilidad. Boletín
epidemiológico semanal 1998; 6:149-156.
7.
Medrano MJ, Almazán J, Sierra MJ, Olalla MT. Situación epidemiológica de las
enfermedades cardiovasculares arterioscleróticas: prevalencia de factores de riesgo.
Boletín epidemiológico semanal 1998; 6:157-164.
8.
Boix R, Medrano MJ, Almazán J. Actualización de la mortalidad por enfermedades
cardiovasculares arterioscleróticas: enfermedad cerebrovascular y enfermedad isquémica
del corazón Boletín Epidemiológico semanal 2000; 8: 77-84
9.
Villar F, Banegas JR, Rodríguez F y Rey J. Mortalidad cardiovascular en España y sus
comunidades autónomas (1975-1992).Med Clín(Barc) 1998;110:321-327
10. Grundy S, Bazzarre T, Cleman J, D’Agostino R, Hill M, Houston-Miller N et al. Prevention
Conference V. Beyond Secondary Prevention: Identifying the High-Risk Patient for Primary
Prevention. Medical office assessment. Circulation 2000;101:e3-e11
11. Smith S, Greenland P, Grundy S. Prevention conferenc V. Beyond: Secondary Prevention:
Identifying the High-Risk Patient for Primary Prevention. Executive Sumary. Circulation
2000;101:111-116
12. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the
Nutrition Committee, American Heart Association. Circulation 1997;96:3248-50.
13. Fletcher GF, Balady G, Blair SN, Blumenthal J, Caspersen C, Chaitman B et al. Statement
on exercise: benefits and recommendations for physical activity programs for all
Americans: a statement for health professionals by the Committee on Exercise and
Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association.
Circulation 1996; 94:857-862
202
Bibliografía
14. Riva-Rocci S. Un Sfingomanometro nuovo. Gaz Med Torino 1896; 47:981-996.
15. Riva-Rocci S. Un Sfingomanometro nuovo. Gaz Med Torino 1896; 47:1001-1017.
16. Korotkoff NS. Kvopruso o metodoach eezldovania krovyoanovo-davlenia. Izv Imperatoor
Vorenno. Med Akad 1905;11:365-367.
17. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart
disease: The Framingham Study. Dis Chest 1969; 56:43-52.
18. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role
blood pressure in stroke. The Framingham Study. JAMA 1970; 214:301-310.
19. Kannel WB, Castelli WP, McNamara PM, et al. Role of blood pressure in the development
of congestive heart failure. The Framingham Study. N Engl J Med 1972; 287:781-787 .
20. Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog.
Cardiovascular Dis 1974; 7:5-24.
21. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham
Study. Am J Publ Health 1988; 78:676-679.
22. Sytkowski A, D’Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term
sustained hypertension, long-term treatments, and cardiovascular mortality. The
Framingham heart study 1950 to 1990. Circulation 1996; 93:697-703.
23. Kannel WB. Factores de riesgo en la enfermedad coronaria: experiencia del seguimiento
durante tres décadas del estudio de Framingham. Hipertensión y Arteriosclerosis 1989;
1:77-86.
24. Stamler J,Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk
premature death from coronary heart disease continuous and grated? Findings in 35.222
primary screeness of Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;
256:2823-2828.
25. The WHO Monica Project Geographical variation in the major risk factors of coronary heart
disease in men and women aged 35-64 years. World Health Stat Q 1988; 41:115-129.
26. Burt VL, Whelton PK, Rocella EJ, Brown C, Cutler JA, Higgins M. Prevalence of
hypertension in the US adult population: Results from the Third National Health and
Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305-313.
27. Perloff D, Sokolow M. Ambulatory blood pressure: Mortality and morbidity. J Hypertens
1991;9(suppl 8):S31-S33
28. Lew EA. High blood pressure, other risk factors and longevity: The insurance viewpoint.
Am J Med 1973; 55:281-294.
29. Pickering GW. The Nature of Essential Hypertension. London: J & A Churchill; 1961.
30. Hansson L, Kilander L, Ohrval M. Epidemiology of Hypertension. In Oparil-Weber (ed),
Hypertension a companion to Brenner and Rector’s the kidney. Pennsylvania: Saunders
Company; 2000.p. 4-19.
203
Bibliografía
31. Leon DA, Koupilova I, Lithell HO, Berglund L, Mohsen R, Vagero D et al. Failure to realise
growth potential in uterus and adult obesity in relation to blood pressure in 50 years old
Swedish men. BMJ 1996; 312:401-406.
32. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure. The Sixth Report of the Joint National Committee on Prevention,
Detection, Evaluation and Treatment of High Blood Pressure" (JNC VI). Arch Intern Med
1997; 157:2413-46.
33. Guidelines subcommittee. 1999 World Health Organization-International Society of
Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151183
34. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke
and coronary heart disease. (Part 1). Prolonged differences in blood pressure: prospective
observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
35. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure,
stroke and coronary heart disease. (Part 2), short term reductions in blood pressure:
overview of randomised drug trails. Lancet 1990;335:827-38.
36. Kannel W. Blood pressure as a cardiovascular risk factor. JAMA 1996; 275:1571-1576
37. Anderson O, Almagren T, Peterson B, Samuelson O, Hedner T, Wilhelmsen L. Survival in
treated hypertension: follow up study after two decades. BMJ 1998;317:167-71.
38. Whelton PK. Epidemiology of the hypertension. Lancet 1994;344:101-106
39. Hoes A, Grobbee D, Lubsen J. Does drug treatments improve survival? Reconciling the
trials in mild-to moderate hypertension. J Hypertens 1995;13:805-811.
40. Banegas JR, Rodríguez-Artalejo F, De la Cruz JJ, De Andrés B, Del Rey J. Mortalidad
relacionada con la hipertensión y la presión arterial en España. Med Clin (Barc)
1999;112:489-494
41. Banegas JR, Villar F, Pérez C, Jiménez J, Gil E, Muñiz J, Juanes R. Estudio
epidemiológico de los factores de riesgo cardiovascular en la población española de 35 a
64 años. Rev San Hig Pub 1993;46:1.173-1.179
42. Pardell H. Fármaco economía de la hipertensión arterial. Madrid. SEH/LELHA. 1996.
43. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del
estudio Controlpres 98. Hipertensión 1998; 15:298-307.
44. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of
intensive blood pressure lowering and low dose aspirin in patients with hypertension:
principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet
1998; 351:1755-62.
45. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P et al. Trends in the
prevalence, awareness, treatment, and control of hypertension in the adult US population:
data from the health examination surveys, 1960 to 1991.Hypertension 1995;26:60-69.
204
Bibliografía
46. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood
pressure, cholesterol and stroke in Eastern Asia. Lancet 1998; 352:1801-1807.
47. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke:
13.000 strokes in 45.000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653.
48. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure
and end-stage renal disease in men. N Engl J Med 1996; 334:13-18.
49. Abadal Tomas L. Epidemiología de la arteriosclerosis coronaria. Factores de riesgo
coronario. Medicine 1996;7:872-878
50. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of
stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
51. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk.J
Hypertens Suppl. 1994;12:5-14.
52. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH et al, for Systolic
Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind
comparison of placebo and active treatment for older patients with isolated systolic
hypertension. Lancet 1997;350:757-764.
53. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the
elderly (STONE). J Hypertens 1996; 14:1237-1245.
54. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (SystChina) Collaborative Group. Comparison of active treatment and placebo for older Chinese
patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829.
55. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al.,for the CAPPP
Study Group. Principal results of the Captopril Prevention Project (CAPPP). Lancet
1999;353:611-616 .
56. The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an
angiotensin-converting enzyme inhibitor, Ramipril, on cardiovascular events in high-risk
patients. N Engl J Med 2000; 342:145-53.
57. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of
macrovascular and microvascular complications type 2 diabetes:UKPDS 39.BMJ 1998;
317:713-720
58. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of
macrovascular and microvascular complications in type 2 diabetes:UKPDS 38.BMJ 1998;
317:703-713
59. Mulrow C, Lau J, Cornell J, Brand M. Pharmacoterapy for hypertension in elderly
(Cochrane Review). En The Cochrane Library, Issue 4. Oxford: Update Software 1999.
60. Gueyffier F, Froment A, Gouton M. New metaanálisis of treatment trials of hypertension
improving the estimate of therapeutic benefit. J Hum Hypertens 1996;10:1-8.
61. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. Report of the
U.S. Preventive Services Task Force. Baltimore: Willians and Wikins, 1996.
205
Bibliografía
62. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in
England: results from the health survey for England 1994. J Hypertens 1998; 16:747-752.
63. Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, et al. Mortality in
patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4:141-156.
64. Levy D, Garrison R, Savage D, Kannel W, Castelli W. Prognostic implications of
echocardiography determined left ventricular mass in the Framingham Heart Study. N Engl
J Med 1990; 322:1561-1566.
65. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the
community: is the rule of halves still valid? J Hum Hypertens 1997; 11:213-220.
66. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the
hypertensive population. Lancet 1997; 349:454-457.
67. Banegas JR, Rodríguez Artalejo F, De la Cruz JJ, Guallar-Castillón P, Del Rey J. Blood
pressure in Spain. Distribution, awareness, control and benefits of a reduction in average
pressure. Hypertensión 1998;32:998-1.002.
68. Coca A. Control de la hipertensión arterial en España. Resultados del estudio
Controlpress95. Hipertensión 1995; 12:182-188.
69. World Health Organization. World Health Statistics Annual. Geneva: World Health
Organization; 1995.
70. Castelli WP. The trigliceride issue: a view from Framingham. Am Heart J 1986;112:432437.
71. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum
Cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-373.
72. Wilson WP, High-density lipoprotein, low-density lipoprotein and coronary artery disease.
Am J Cardiol 1990;66:7A-10A.
73. Gordon DJ, Probsteeld JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. Highdensity lipoprotein cholesterol and cardiovascular disease: four prospective American
studies. Circulation 1989; 79:8-15.
74. Summary of the second report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
JAMA. 1993;269:3015-3023.
75. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic
heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;
97: 1029-1036.
76. Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemy and elevated
lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol
1996; 77: 1179-1184.
77. Task Force on Risk Reduction (AHA). Cholesterol screening in asymptomatic adults: no
cause to change. Circulation. 1996;93:1067-1068
206
Bibliografía
78. Sociedad Española de Arteriosclerosis, Sociedad Española de Medicina Interna y Liga de
la Lucha contra la Hipertensión Arterial. Recomendaciones para la prevención primaria de
la enfermedad cardiovascular. Clin Invest Arterioesclerosis 1994; 6:62-102.
79. Maiques A, Morales MM, Franch M, Doménech A, Moreno P García JM. Cálculo del riesgo
coronario de los pacientes incluidos en el Programa de Actividades Preventivas y de
Promoción de la Salud. Aten Primaria 1995; 15:30-36.
80. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HAW. Systematic review
of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ
1998; 316:1213-1220.
81. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering
in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study
(4S). Lancet 1994; 344:1383-1389.
82. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al., for the West
of Scotland Coronary Prevention Study group. Prevention of coronary heart disease with
pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
83. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al., for the
Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary
events after myocardial infarction in patients with average cholesterol levels. N Engl J Med
1996; 335:1001-1009.
84. Downs JR, Cleareld M, Weis S, Whitney E, Shapiro DR, Beere PA et al. for the
AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with
lovastatin in men and women with average cholesterol. JAMA 1998; 279: 1615-1622.
85. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in
patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl
J Med 1998; 339:1349-1357.
86. La Rosa J, He J, Vupputuri S. Effect of Statins on Risk of Coronary Disease.A Metaanalysis of Randomized Controlled Trials. JAMA 1999;282:2340-2346
87. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary
prevention of coronary heart disease: guidance from Framingham: a statement for
healthcare professionals from the American Heart Association Task Force on Risk
Reduction: American Heart Association. Circulation. 1998;97:1876–1887.
88. Danes J, Collins R, Peto R. Lipoprotein(a) and Coronary Heart Disease. Meta-Analysis of
Prospective Studies. Circulation. 2000;102:1082-1085.
89. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb.
1991;11:2-14
90. Krauss RM. Dense low-density lipoproteins and coronary artery disease. Am J Cardiol.
1995; 75:53B-57B.
91. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40
years' observations on male British doctors. BMJ 1994; 309:901-911.
207
Bibliografía
92. Prescott E, Hippe M, Schnohr P, Ole H, Vestbo J. Smoking and risk of myocardial
infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043-1047
93. He J, Vupputuri S, Allen K, Prerost R, Hughes J, Whelton P. Somking and the risk
coronary heart disease. A meta-analysis of epidemiologic studies. N Engl J Med 1999;
340:920-6.
94. Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term
prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year
follow-up of the Primary Prevention Study in Gothenburg, Sweden. Eur Heart J 1997;
18:754-61.
95. U.S. Department of Health and Human Services. The Health Benefits of Smoking
Cessation: A Report of the Surgeon General. Rockville, MD: Center for Disease Control,
Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and
Health; DHHS publication nº. (CDC) 90-8416; 1990.
96. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al.
Hyperinsulinemia is an independent risk factor for ischemic heart disease. N Engl J Med
1996; 334:952-957.
97. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996;
347:949-950.
98. Iglesias G, Rodríguez J, Barriales V. Factores de riesgo coronario. Med clin (Barc) 1995;
104:142-147.
99. Pyorala M, Miettinen H, Laakso M, Pyorala K. Plasma insulin and all-cause,
cardiovascular, and non cardiovascular mortality: the 22-year follow-up results of the
Helsinki Policemen Study. Diabetes Care. 2000; 23:1097-102.
100. Wei M, Gaskill S, Haffner S, Stern M. Effects of Diabetes and level of glycaemia on all
cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998;
1167-75.
101. Levy D, Garrison RJ, Savage DD. Left ventricular mass and incidence of coronary heart
disease in an elderly cohort. The Famingham Study. Ann Intern Med 1989;11:101-107
102. Coca A, De la Figuera M, López Sendon JL, Sagastagoitia JD, Gabriel R, Barajas JJ et al.
Prevalencia de hipertrofia ventricular izquierda en la hipertensión arterial esencial. Estudio
VITAE. Hipertensión 1996; 13:13-14
103. Moster A, D’Agostino R, Silbershatz H, Sytkowski P, Kannel W, Grobbee D, Levy D.
Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular
hypertrophy from 1950 to 1989. N Engl J Med 1999; 340:1221-7.
104. Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet and cardiovascular diseases: a
statement for healthcare professionals from the Nutrition Committee, American Heart
Association. Circulation. 1999;99:178-182.
208
Bibliografía
105. Woodward M, Lowe G, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for
coronary heart disease and mortality in middle-aged men and women: the Scottish Heart
Health Study. Eur Heart J 1998; 19:55-62.
106. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review
of the literature. Ann Intern Med 1993; 118:956-963.
107. Kannel WB, Wolf R, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular
disease. The Framingham Study. JAMA 1987;258:1183-1186
108. Meade TW, Mellows S, Brozovick M, Miller GJ, Cakrabarti RR, North WR. Haemostatic
function and ischaemic heart disease: Principal result of Northwick Park Heart Study.
Lancet 1986;2:533-537.
109. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the
risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol. 1997;
17:1539-44
110. Rimm EB, Stampfer MJ, Ciovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body
size and fat distribution as predictors of coronary heart disease among middle-aged and
older US men. Am J Epidemiol 1995; 141:1117-1127.
111. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of
cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;
325:373-381.
112. Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for
diabetes and cardiovascular disease. Arteriosclerosis 1986;6:123-130.
113. Calle E, Thun M, Petrelli J, Rodriguez C, Heath C. Body-Mass Index and Mortality in a
prospective cohort of US adults. N Engl J Med 1999; 341:1097-105
114. Aranceta J, Perez C, Serra L, Ribas L, Quiles J, Vioque J, Foz M. Prevalencia de la
obesidad en España: estudio SEEDO’97. Med Clin (Barc) 1998; 111:441-445.
115. Banegas JR, Villar Álvarez F y Rodrigues Artalejo F. Enfermedades cardiovasculares y
sus factores de riesgo. Importancia sanitaria en España. Hipertensión 1996; 13: 329-338
116. Grupo Colaborativo peso-HTA. Estudio peso-HTA. Prevalencia de sobrepeso y obesidad
en la población hipertensa española mayor de 39 años atendida en Centros de Salud.
Hipertensión 1996;13:210-219 .
117. Arakawa K. Effect of exercise on hypertension and associated complications. Hypertens
Res 1996; 19 (Suppl 1):S87-S91.
118. Colditz GA, Stampher M, Willet W, Rosner B, Sperer FE, Hennekens C. A Prospective
study of parenteral history myocardial infarction and coronary heart disease in woman. Am
J Epidemiol 1986;123:48-58.
119. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated
with age and sex of parenteral heart disease in the Framingham Study. Am J Cardiol
1989;64:555-559
209
Bibliografía
120. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis.
Science 1986; 232:34-47
121. Humphries SE. DNA polymorphisms of the apolipoprotein genes. Their use in the
investigation
of
the
genetic
component
of
hiperlipidemia
and
atherosclerosis.
Atherosclerosis 1998;72:89-108.
122. Balanya J, Marsal S, LaVille A, Margalet J, Turner PR, Masana L. Polimorfismo del gen de
la apolipoproyeina A-I en población sana. Relación con las lipoproteinas de alta densidad.
Med Clin (Barc) 1993;100:90-93.
123. Levitsky LL, Scanu AM, Gould SH. Lipoprotein (a) levels in black and whites children and
adolescents with IDDM. Diabetes care 1991;14:238-289
124. Marmot MG, Rose G, Shipley MJ, Thomas BJ. Alcohol and mortality: a U-shaped curve.
Lancet 1981; 1: 580-3
125. Rimm ER, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption
and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits?. BMJ
1996; 312:731-736.
126. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, et al. Alcohol
consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997;
337:1705-1714.
127. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged
British men. Stroke 1996; 27:1033-1039.
128. Beilin LJ. Alcohol and hypertension. Clin Exp Pharmacol Physiol 1995 ;22:185-8
129. Anderson KM, Wilson PWF, Odell PM, Kannel WB, Un update coronary risk profile, A
stament for health professionals. Circulations 1991;83:356-362
130. Wilson P; D’Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W. Prediction of
Coronary Heart Disease Using Risk Factor Categories. Circulation. 1998;97:1837-1847
131. Grundy S. Primary Prevention of Coronary Heart Disease: Integrating Risk Assessment
With Intervention Circulation 1999; 100: 988-998.
132. Grundy S, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of Cardiovascular
Risk by Use of Multiple-Risk-Factor Assessment Equations A Statement for Healthcare
Professionals From the American Heart Association and the American College of
Cardiology. Circulation 1999; 100: 1481-1492.
133. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of
coronary heart disease in clinical practice. Recommendations of the Second Joint Task
Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19:
1434-1503.
134. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for
cholesterol lowering for primary prevention of coronary heart disease. Lancet
1995;346:1467-71.
210
Bibliografía
135. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin JN. Targeting lipid-lowering drug
therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet
1996;384:387-388.
136. Wallis E, Ramsay L, Haq I, Ghahramani P, Jackson P, Rowland K Yeo W. Coronary and
cardiovascular risk estimation for primary prevention:validation of new Sheffield table in the
1995 Scottish health survey population. BMJ 2000; 320:671-6
137. Shaper AG, Pococok SJ Philips AN, Walter M. Identifying men at high risk of heart
attacks:stategy for use in general practice. BMJ 1986;293:474-479.
138. Tunstall-Pedoe H. The Dundee coronary risk-disk for management of change in risk
factors. BMJ 1991;303:744-747.
139. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of followup at 8 years. Eur Heart J 1998; 19 (Suppl A): A2-A11.
140. Jackson R, Barham P, Bills J, Birch T, McLennan I, MacMahon S, et al. Management of
Raised Blood Pressure in New Zealand: a discussion document. BMJ 1993; 307:107-110.
141. New Zealand Guidelines Group. The Management of Mildly Raised Blood Pressure in New
Zealand 1997. URL disponible en: http://www.nzgg.org.nz/guides/blodpresure/index.htm
142. Jackson R: Update New Zealand cardiovascular disease risk-benefit prediction guide. BMJ
2000;320:709-10
143. Vázquez A, Maiques A, y Vilaseca J. Concepto y utilidad del riesgo coronario en el manejo
de la hipercolesterolemia. FMC 1997;4:536-543.
144. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function
valid for northen European population? A comparison of methods for estimating absolute
coronary risk in high-risk men. Heart 1999;81:40-4.
145. Chassin M, Galvin R. La National Round table on health care quality del institute of
medicine. La urgente necesidad de mejorar la calidad asistencial. JAMA (ed.esp)
1999;8:128-136.
146. Otero Puime A, Saturno Hernández PJ, Marquet Palomer R. Mejora de la calidad en
Atención Primaria. En: Martín Zurro A y Cano Pérez JF, editores. Atención Primaria.
Conceptos, organización y practica clínica. 4ª ed. Barcelona: Mosby/Doyma; 1999. p.274288.
147. Vuori HV. El control de calidad en los servicios sanitarios. Barcelona: Masson; 1989.
148. Palmer RH. Evaluación de la asistencia ambulatoria. Principios y práctica. Ministerio de
Sanidad: Madrid; 1989.
149. Donabedian A. Apreaches to assessment: What to asses. In evaluating the quality of
medical care. Milbank Memorial Fund Quarterly 1966;44:167-170.
150. Donabedian A. Una aproximación a la monitorización de la calidad asistencial(I). Control
de calidad asistencial 1991; 6:1-6.
151. Donabedian A. Una aproximación a la monitorización de la calidad asistencial(II). Control
de calidad asistencial 1991; 6:31-39.
211
Bibliografía
152. Donabedian A. La calidad de la atención médica. México: La Prensa Médica Mexicana;
1984.
153. Prados D, Leiva F. Medición de la calidad en función de los resultados. En: Saturno PJ,
editor. Tratado de Calidad en atención primaria. Madrid: Du Pont Pharma; 1997.p.111133.
154. Saturno PJ. Curso de calidad asistencial en Atención Primaria. Madrid: Universidad de
Murcia y Du pont Pharma; 1997.
155. Saturno PJ. Tratado de Calidad en atención primaria. Madrid: Du Pont Pharma; 1997.
156. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A
systematic review of the effect of continuing medical education strategies. JAMA
1995;274:700-704.
157. Connell D, Henry D, Tomlins R. Randomised controlled trial of effect feedback on general
practitioners prescribing in Australia. BMJ 1999; 318:507-511.
158. Field MJ, Lorh KN, ed. Clinical practice guidelines. Directions for a new program.
Washington DC: National Academy Press, 1990 .
159. Jovell AJ, Navarro-Rubio MD. Guías de práctica clínica. FMC 1995; 2:152-155.
160. Grimshaw JM, Russell IT. Achieving health care through clinical guidelines I. Developing
scientifically valid guidelines. Quality in health care 1993; 2:243-248.
161. Grimshaw JM, Russell IT. Achieving health gain thought clinical guidelines. II: Ensuring
guidelines change medical practice. Quality in health care 1994; 3:45-52.
162. Baker R, Fraser R. Development of review criteria: linking guidelines and assessment of
quality. BMJ 1995; 311:370-373
163. Conroy M, Shannon W. Clinical guidelines: their implementation in general practice. Br J
Gen Pract 1995; 45:371-375.
164. Instituto Nacional de la Salud. Subdirección General de Atención Primaria. Cartera de
servicios de atención primaria, definiciones, criterios de acreditación, indicadores de
cobertura y normas técnicas mínimas. 2ª edición. Madrid: Secretaria General del
INSALUD; 1997.
165. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K . Prevención de la
cardiopatía coronaria en la práctica clínica. Resumen de las recomendaciones del
segundo grupo de trabajo conjunto de la sociedad europea y otras sociedades sobre
prevención coronaria. Iberoamerican Journal of Hypertension 1999; 4:77-85.
166. Moreno Regidor A. Mora Santiago C, García Ortiz L, Arganda Maya J, Alba Pérez I, Gil
Gregorio A.¿Que está pasando con los Hipertensos que tantas veces vemos en las
consultas?. En II Jornadas Astur-Castellano-Leones de Medicina Familiar y Comunitaria.
Valladolid: SCLMFyC; 1997.p.123.
212
Bibliografía
167. Arganda Maya J. Mora Santiago C, García Ortiz L, Moreno Regidor A, Alba Pérez I, Gil
Gregorio A ¿El control periódico del Hipertenso reduce el riesgo cardiovascular? En II
Jornadas Astur-Castellano-Leones de Medicina Familiar y Comunitaria. Valladolid:
SCLMFyC; 1997.p.124.
168. Maderuelo Fernández J A, Iglesias Carrero P, Melón Barrientos L, Rodríguez Corral T,
Arganda Maya , Mora Santiago Mª C y Garcia Ortiz L. Fiabilidad de los resultados que
utilizan la historia clínica como fuente de datos. III Congreso de la Sociedad CastellanoLeonesa de Cardiología. Salamanca: SOCALEC; 1998.p.45.
169. The expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of
the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diab Care
1997;20:1183-1197.
170. World Health Organization. Arterial Hypertension. Report of WHO Expert Committee. WHO
Technical Report Series 628. Geneva, Switzerland: World Health Organization;1978.
171. Frohlich ED, Grim C, Labarthe DR. Recommendations for human blood pressure
determination by sphygmomanometers. Report of a special task force by the steering
committee. American Heart Association. Hypertension 1988; 11:209A-222A.
172. American Society of Hypertension. Recommendations for routine blood pressure
measurement by indirect cuff sphygmomanometers. Am J Hypertens 1992;5:207-209.
173. Altisant R, Cordoba R, Martin-Moros JM. Criterios operativos para la prevención del
alcoholismo. Med Clin (Barc) 1992;99:584-588.
174. Castellano Reyes C, Pérez de Juan R, Espinosa Caliani JS. Electrocardiografía Clínica.
Barcelona: Mosby/Doyma 1997.
175. Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH et al. Epi Info Versión
6; a word processing, database, and statistics program for epidemiology on microcomputers.
Atlanta: Center for Disease Control and Prevention; 1994.
176. Norusis MJ, SPSS/PC+. Advanced Statistics, Versión 9.0. Chicago: SPSS;1998.
177. Stergiou G, Thomopoulou G, Skeva I and Mountokalis T. Prevalence, Awareness,
Treatament, and Control of Hypertension in Greece. The Didima Study. Am J Hypertens
1999;12:959-965.
178. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness,
treatment, and control of hypertension in Canadá. Am J Hypertens 1997;19:1097-1102.
179. Gasse C, Gense H, Stieber J, Döring A, Liese AD and Keil U. Assessing hypertension
management in the community: trends of prevalence, detection, treatment, and control of
hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertens 2001; 15:
27-36.
180. Grupos de trabajo en hipertensión. Situación actual de la detección, tratamiento y control
de la hipertensión arterial en España. Madrid: Liga Española para la lucha contra la
Hipertensión arterial; 1995. p.47-50.
213
Bibliografía
181. Alonso M, Condes E, Saa R, Valdivia H, Del Rio, M. Seguimiento de una cohorte de
pacientes con hipertensión arterial en atención primaria. Atención primaria 1996; 17: 575579.
182. Muñoz M, García A, López C, Corrales E, Ruano J, Hernández F. Programa de
actividades preventivas y de promoción de la salud en el adulto. ¿Cómo lo cumplimos?.
En IV Congreso Astur Castellano-Leones de Medicina de Familia y Comunitaria. VI
Jornada Nacional de Universidad y Medicina de Familia. Salamanca: SCLMFyC;
1999.p.79.
183. Subias PJ, Bauzka K, Casanovas E, García JR, Iglesias M, Jiménez J, Martín-Rabadan M,
Moreno J y Perula L. Estudio de efectividad PAPPS(1998) y resultados preliminates de la
evaluación del PAPPS (1999). Atención Primaria 1999; 24 (Supl 2):11-17.
184. Salleras Sanmartí. Salud del adulto. En: Piedrola G, editor. Medicina preventiva y salud
publica.8ª ed. Barcelona: Salvat; 1988. p. 933-46
185. Van Drenth B; Hulscher M; Van Der Wouden J; Mokkink H; Van Well C; Grol R. Relations
between practice organization and cardiovascular risk factor recording in general practice.
Br J Gen Pract. 1998. 48: 1054-1058.
186. Gerencia de Atención primaria de Salamanca.INSALUD. Evaluación de Cartera de
Servicios. Salamanca:INSALUD; 1994.
187. Subdirección General de Atención primaria. INSALUD. Evaluación de cartera de servicios.
Madrid: INSALUD; 1994.
188. Villaplana R, Tobias J. Implementación del protocolo de hipertensión en un área básica de
salud como base para una auditoria médica. Aten Primaria 1994; 13: 70-72
189. McAlister FA, Teo KK, Lewanczuk RZ, Wells G, Montague TJ. Contemporary practice
patterns in management of newly diagnosed hypertension. CMAJ 1997; 157:23-30.
190. Mashru M, Lant A. Interpractice audit of diagnosis and management of hypertension in
primary care.Educational intervention and review of medical records. BMJ 1997; 314:942-6
191. National Center for Health Statistics. Healthy People 2000 review, 1994. Hayattsville,
Md.:Public health Service; 1995. (DHHS publication nº(PHS) 95-1256-1.
192. Márquez E, Casado JJ, Gutiérrez Mª C, Jiménez Mª C, Franco C, Moreno JP.
Epidemiología de la hipertensión arterial en la población general adulta de la zona básica
de salud “La Orden” de Huelva. Hipertensión 1995; 12:225-231.
193. Coca A, Soler J., Plana J., Roma J. Control de la hipertensión arterial en unidades de
hipertensión de hospitales comarcales. Resultados de un modelo de asistencia
multicentrica protocolizada. Hipertensión 1997; 14: 14-26
194. Berlowitz R, Ash A., Hicjey E, Friedman R, Glickman M, Kader B, Moskowitz M.
Inadequate Management of Blood Pressure in a Hypertensive Population. N Engl J Med
1998; 339:1957-63.
214
Bibliografía
195. Alexander M, Tekawa I, Hunkeler E, Feirman B, Rowell R, Selby J, Massie B, Cooper W.
Evaluating Hypertension Control in a Managed Care Setting. Arch Intern Med 1999; 159:
2673-2677
196. Puras A, Sanchis C. El control de la hipertensión arterial en España: El objetivo mas
importante pero mas olvidado de los últimos años. Med Clin (Barc) 1997;108:734-736.
197. Puras A. Causas del mal control de la presión arterial en España. Atención Primaria 1998;
21: 638-644.
198. Grupo de Trabajo sobre Incumplimiento. Incumplimiento terapéutico en los ancianos. Med
Clin (Barc) 1993; 100: 736-739.
199. Luque M, Martell N, Fernández Pinilla MC. Actitud del médico de atención primaria ante el
paciente hipertenso. Hipertensión 1995; 12: 80-86.
200. Luque M. Control de la hipertensión arterial en España, 1996. Hipertensión 1996; 13 (Supl
4): 21-24.
201. Castelli WP, Garrison RJ, Wilson PWF, Abbot RD, Kalousdiam S, Kannel WB. Incidence of
coronary heart disease and lipoprotein cholesterol level. JAMA 1986;256:2835-38.
202. Martell N, Fernández C, Luque M. Estudio ESFINGO. Hipertensión 1998;15: 351-356
203. Muñiz J, Juane R, Hervada J, López Rodríguez I, Castro Beiras A. Concentraciones
séricas de colesterol en la población gallega de 40-69 años de edad. Clin Invest Arterioscl
1991; 3: 143-148.
204. Aranda P, Villar J. Estudio epidemiológico andaluz sobre factores de riesgo vascular.
Estudio Al-Andalus 90. Sevilla: Consejería de Salud; 1993.
205. Rodríguez JC, Calonge S, Bichara G. Prevalencia de los factores de riesgo de cardiopatía
isquémica en la isla de Lanzarote. Med Clin (Barc) 1993; 101: 45-50.
206. Tormo Díaz MJ, Navarro Sánchez C, Chirlaque López MD, Pérez Flores D. Factores de
riesgo cardiovascular en la región de Murcia, España. Rev Esp Salud Pública 1997; 71:
515-529.
207. Masía R, Pena A, Marrugat J, Sala J, Pavesi M, Covas J et al. High prevalence of
cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction
incidence. J Epidemiol Community Health 1998; 52: 707-715.
208. García Closas R, Serra Majem L, Chacón Castro P, Olmos Castellvell M, Ribas Barba L,
Salleras L. Distribución de la concentración de lípidos séricos en una muestra
representativa de la población adulta de Cataluña. Med Clin (Barc) 1999; 113: 6-12.
209. Segura Fragoso A, Rius Mery G. Factores de riesgo cardiovascular en una población rural
de Castilla-La Mancha. Rev Esp Cardiol 1999; 52: 577-588.
210. Martínez MA, Bueno A, Fernández MA, Garcia M, Delgado M, Gálvez R. Prevalencia de
factores de riesgo cardiovascular en población laboral. Med Clin (Barc) 1995;195.321-326
211. Plaza I, Villar F, Mata P, Pérez F, Maiquez A, Casanovas JA et al. Control de la
Colesterolemia en España 2000. Un instrumento para la prevención cardiovascular. Rev
Esp Cardiol 2000;53: 815-837
215
Bibliografía
212. Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the
health care system. BMJ 1999;318:182-5
213. Richmond R .Opening the window of opportunity: encouragement patients to stop
smoking. Heart 1999; 81:456-458
214. Comas A, Suárez R, López MªL, Cuesto A. Coste-efectividad del consejo sanitario
antitabaco en atención primaria de salud. Gac Sanit 1998; 12:126-132
215. Stapleton JA, Lowin A, Russel MAH. Prescription of transdermal nicotine patches for
smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999;
354:208-13
216. Huighes J, Goldtein M, Hurt R, Shiffman S. Progresos recientes en la farmacoterapia del
tabaquismo. JAMA (ed.esp) 1999; 8:305-311
217. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR. A Controllers
Trial of Susteined-release Bupropion, a Nicotine Patch,or Both for Smoking Cessation. N
Engl J Med 1999;340:685-691
218. Ministerio de Sanidad y Consumo. Encuesta Nacional de Salud de España 1997. Madrid:
Ministerio de Sanidad y Consumo 1998.
219. Fiore MC, Baker TB. Smoking cessation treatments and the good doctor club. Am J Public
Health 1995;85:161-163.
220. Rayo I, Marín E. Vino y Corazón. Rev Esp Cardiol 1998; 51:435-449.
221. Law M, Wald N. Why heart disease mortality is low in France: the time lag explanation.
BMJ 1999; 318:1471-80.
222. Albert C, Manson J, Cook N, Ajani U, Gaziano M, Hennekens C. Moderate alcohol
consumition and the risk of sudden cardiac death among US Male Physicians. Circulation
1999. 100-944-950.
223. Valmadrid C, Klein R, Moos S, Klein B, Cruisckhanskz K. Alcohol intake and the risk of
coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA 1999;
282:239-246.
224. Romelsjo A, Leifman A. Association between alcohol consumption and mortality,
myocardial infarction, and stroke in 25 years follow up of 49618 young Swedish men.
BMJ1999; 319:812-816
225. Sesso H, Stampfher M, Rosner B, Hennekens C, Mason J, Gaziano M. Seven-Year
Changes in Alcohol Consumption and subsequent risk of cardiovascular disease in men.
Arch Intern Med 2000;160:2605-2612.
226. Mediavilla G, Fernández Torres C. Aliaga Martínez L. Importancia del Índice de masa
corporal en una unidad de hipertensión arterial. Hipertensión 1997; 14:117-120:
227. Sociedad Española para el estudio de la obesidad (SEEDO). Consenso español 1995
para la evaluación de la obesidad y para la realización de estudios epidemiológicos. Med
Clin (Barc) 1996;107:782-787
216
Bibliografía
228. Hieden S, Schneir KA.Obesity and hypertension: epidemiological aspects of the
relationship. J Human Hypertens 1990;4:431-435
229. Armario Garcia P, Hernández del Rey P, Gasullas Roso JM, Pardel-Alenta H. Obesidad e
hipertensión arterial. Estudio transversal de prevalencia en la población de Hospitalet de
Llobregat. Rev. Clin Esp 1990;187:223-228.
230. Plans P, Espunas J, Romero N, Barahona M, Ruigomez J, Pardell H, Salleras L.
Asociación entre hipertensión arterial, obesidad e hipercolesterolemia en una muestra de
la población adulta de Cataluña. An Med Inter 1994;11:278-284
231. Gabalda L,Ramon JM,Torras MG,Martines-Ameros A,Rama H,Sarrias X. Prevalencia de
factores de riesgo cardiovasculares en una población de hipertensos esenciales. Rev Esp
Cardiol 1993;46:626-632.
232. Álvarez Torices JC, Franc Nadal J, Álvarez Guisasola F, De Pablo Pons ML, Hernández
Mejia R, Cueto Espinar A. La obesidad en la provincia de León. Distintos criterios,
diferentes prevalencias. Aten Primaria 1992; 10:1013-1018
233. Kuczmarsy RJ, Prevalence of overweight and weigh gain in the United States. Am J Clin
Nutri 1992;55 (Supl) 495-502
234. Gress T, Nieto J, Shahar E, Wofford M Bracanti F. Hypertension and Antihypertensive
therapy as risk factors for typo 2 diabetes mellitus. N Engl J Med 2000;342:905-12
235. Rodríguez L, Navarro A, Sánchez J. Utilidad del electrocardiograma en el diagnóstico de
hipertrofia ventricular izquierda en la hipertensión arterial esencial. Rev Esp Cardiol 1991;
44:395-399.
236. Lloyd-Jones D, Evans J, Larson M, O’Donnell C, Wilson P, Levy D. Cross-classification of
JNC VI Blood Pressure Stragesand Risk Groups in the Framingham Heart Study. Arch
Intern Med. 1999; 159:2206-2212
237. Dalfo A, Vila MA. Hipertensión arterial e hipertrofia del ventrículo izquierdo. Aten Primaria
1995;16: 82-84
238. Tudor Hart J, Thomas C, Gibbons B, Edwards C, Hart M, Jones J, Jones M, Walton P.
Twenty five years of case finding and audit in a socially deprived community. BMJ
1991;302:1509-13.
239. Jones AF, Walker J, Jewkes C, Game FL, Bartlett WA, Marshall T, Bayly GR .
Comparative accuracy of cardiovascular risk prediction methods in primary care patients.
Heart 2001;85:37-43.
240. Castro JA, Espejo A, Delgado A, Vázquez R, Cardenas S, Orgaz MJ. Programa de
hipertensión y riesgo de cardiopatía isquémica. Aten Primaria. 1994; 14:887-891.
241. Lindholm LH, Ekbom T, Dash C, Eriksson M, Tibblin G, Schersten B, The impact of health
care advice given in primary care on cardiovascular risk. BMJ 1995; 310: 1105-9.
242. Family Heart Study Group. Randomised controlled trial evaluating cardiovascular
screening and intervention in general practice: principal results of British Family heart
Study. BMJ 1994; 308:313-320.
217
Bibliografía
243. Fahey TP, Peters TJ. What constitutes controlled hypertension? Patients based
comparison of hypertension guidelines. BMJ 1996; 313: 93-6.
244. Brotons C, Server M, Pinto X, Roura P, Martin Zurro A. Impacto de los consensos para el
control de la colesterolemia y la hipertensión en España. Med Clin 1997; 108:9-15.
245. O'Connor PJ; Quiter ES; Rush WA; Wiest M; Meland JT Ryu S Impact of hypertension
guideline implementation on blood pressure control and drug use in primary care clinics. Jt
Comm J Qual Improv 1999;25:68-77.
246. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure.
The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment
of High Blood Pressure (JNC-V). Arch Intern Med 1993; 153: 154-183.
247. Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter RA, Myers MG. Report of the
Canadian Hypertension Society Consensus Conference : pharmacological treatment in
essential hypertension. Can Med Assoc J 1993; 149: 575-584.
248. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J et al. Management guidelines in
essential hypertension: report of the second working party of the British Hypertension
Society. BMJ 1993; 306: 983-987.
249. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of 1993
World Health Organization-International Society of Hypertension guidelines for the
management of mild hypertension. BMJ 1993; 307: 1.541-1.546.
250. Ministerio de Sanidad y Consumo. Sociedad-Liga Española para la Lucha contra la
Hipertensión Arterial. Control de la hipertensión arterial en España 1996. Madrid: Idepsa,
S.A.; 1996.p. 1-99.
251. Psaty B, Smith N, Siscovick D, Koepsell T, Weiss N, Heckbert S et al. Health outcomes
associated with antihypertensive therapies used as first-line agents. A systematic review
and meta-analysis. JAMA 1997; 277:739-745
252. Wright J, Lee C, Chambers K. Systematic review of antihypertensive therapies: Does the
evidence assist in choosing a first-line drug.CMJA 1999;161:25-32
253. Wright J. Choosing a first-line drug in the management of elevated blood pressure: What is
the evidence? Thiazide diuretics. CMAJ 2000;163:57-60
254. Wright J. Choosing a first-line drug in the management of elevated blood pressure: What is
the evidence? -Blockers. CMAJ 2000;163:188-92
255. Wright J. Choosing a first-line drug in the management of elevated blood pressure: What is
the evidence? Angiotensin-converting-enzyme inhibitors. CMAJ 2000;163:293-6
256. Grossman E, Messerli F, Goldbourt U. High Blood pressure and diabetes mellitus. Are all
Antihypertensive Drugs Creates Equal. Arch Intern Med 2000; 160:2447-2452.
257. Siegel D, López J. Tendencias en el uso de antihipertensivos en los Estados Unidos.
¿Han modificado los hábitos de prescripción las recomendaciones del V Comité Nacional
de 1993?. JAMA (ed. Esp) 1997;278:1745-1748
218
Bibliografía
258. Prieto M, De Abajo FJ, Montero D, Martín-Serrano G, Madruga M, Palop R. Uso de
antihipertensivos en España, 1985-1995. Med Clin (Barc) 1998; 110: 247-253.
259. Suliman N, Mendiluce A, Alvarez J. The Use of Antihypertensive Therapy in Spain (19861994). AJH 2000;13:607-610
260. García Ruiz A, García Ruiz I, Aranda Lara P, Montesinos A, Martos Crespo F, Sánchez de
la Cuesta F. Estudio sobre los enfermos hipertensos en tratamiento en España durante el
periodo 1990-1993. Rev Esp Salud Publica 1997; 71:9-17.
261. Mateo C, Gil A, Sevillano ML, Barutell L, Lorenzo A, Pérez de Lucas N, Torres M. Calidad
de prescripción de fármacos antihipertensivos en un área de salud. Aten Primaria
2000;25:302-307
262. Wang T, Ausiello J, Stafford R. Trends in antihypertensive drugs advertising 1985-1996.
Circulation 1999; 99:2055-2057.
263. Nobrega FT; Morrow GW; Smoldt RK; Offord KP Quality assessment in hypertension:
analysis of process and outcome. N Engl J Med 1977;296(3):145-8
264. Haynes RB, Gibson ES, Taylor DW, Bernholz CD and Sackett DL. Process versus
outcome in hypertension: a positive result. Circulation 1982;65:28-33.
265. Thomson O’Brien MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL. Audit
and feedback: effects on professional practice and health care outcomes. The Cochrane
Library 1999 Issue 3.
266. Thomson O’Brien MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Hervey EL. Audit
and feedback versus alternative stretegies:effects on professional practice and health cara
outcomes. The Cochrane Library-1999 Issue 3.
267. Freemantle N, Hervey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. Printed educational
materials: effects on professional practice and health care outcomes The Cochrane Library
1999 Issue 3.
268. Oxman A, Thomson M, Davis D, Haynes B. No magic bullets: systematic review of 102
trials of interventions to improve professional practice. Can Med Assoc J 1995;153:14231431.
269. Canadian Task Force on Periodic Health Examination. The periodic health examination.
Can med Assoc J 1979;121:1193-1254.
270. US Department of Health and Human Services. Agency for Health Care Policy and
Research. Acute Pain Management: operative or medical procedures and trauma.
Rockville (MD): The Agency;1993. Clinical Practice Guideline No.1. AHCPR Publication
No. 92-0023. p.107.
219